Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies

被引：18
|
作者：
Tabrizi, Mohammad [1 ]
Funelas, Cherryl [2 ]
Suria, Hamza [3 ]
机构：
[1] AnaptysBio Inc, Preclin Dev, San Diego, CA 92121 USA
[2] Takeda San Francisco, Bioanalyt Dev, San Francisco, CA USA
[3] AnaptysBio Inc, Corp Dev, San Diego, CA 92121 USA
来源：
AAPS JOURNAL | 2010年 / 12卷 / 04期
关键词：
monoclonal antibodies; pharmacodynamics (PD); pharmacokinetics (PK); quantitative pharmacology; translational strategies; DEPENDENT CELLULAR CYTOTOXICITY; ENDOTHELIAL GROWTH-FACTOR; KAPPA-B LIGAND; POPULATION PHARMACOKINETICS; PHASE-I; RECEPTOR ACTIVATOR; MULTIPLE-MYELOMA; BONE METASTASES; CANCER-PATIENTS; HIGH-AFFINITY;
D O I：
10.1208/s12248-010-9220-2
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose- and concentration-response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure-response relationships early on.
引用
收藏
页码：592 / 601
页数：10
相关论文
共 50 条
  • [31] Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies
    Lynch, Carmel M.
    Hart, Bruce W.
    Grewal, Iqbal S.
    MABS, 2009, 1 (01) : 2 - 11
  • [32] Therapeutic monoclonal antibodies for multiple myeloma: an update and future perspectives
    Yang, Jing
    Yi, Qing
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2011, 1 (01): : 22 - 33
  • [33] Production of monoclonal antibodies for therapeutic purposes: A review
    Alejandra, Waller-Pulido
    Irene, Jimenez-Perez Miriam
    Antonio, Gonzalez-Sanchez Fabio
    Patricia, Rojo-Gutierrez Rocio
    Elizabeth, Torres-Anguiano
    Pablo, Aleman-Aguilar Juan
    Rebeca, Garcia-Varela
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 120
  • [34] Monitoring therapeutic monoclonal antibodies in brain tumor
    Ait-Belkacem, Rima
    Berenguer, Caroline
    Villard, Claude
    Ouafik, L'Houcine
    Figarella-Branger, Dominique
    Beck, Alain
    Chinot, Olivier
    Lafitte, Daniel
    MABS, 2014, 6 (06) : 1385 - 1393
  • [35] Principles of the therapeutic use of monoclonal antibodies in oncology
    Fridman, WH
    COMPTES RENDUS BIOLOGIES, 2006, 329 (04) : 255 - 259
  • [36] Tumour angiogenesis inhibition by therapeutic monoclonal antibodies
    Ceze, Nicolas
    Lecomte, Thierry
    Watier, Herve
    M S-MEDECINE SCIENCES, 2009, 25 (12): : 1099 - 1104
  • [37] Pharmacokinetics of therapeutic monoclonal antibodies used in oncology
    Levêque, D
    Wisniewski, S
    Jehl, F
    ANTICANCER RESEARCH, 2005, 25 (3C) : 2327 - 2343
  • [38] Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming
    Mould, Diane R.
    Upton, Richard N.
    Wojciechowski, Jessica
    Phan, Becky L.
    Tse, Stacy
    Dubinsky, Marla C.
    AAPS JOURNAL, 2018, 20 (04):
  • [39] Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming
    Diane R. Mould
    Richard N. Upton
    Jessica Wojciechowski
    Becky L. Phan
    Stacy Tse
    Marla C. Dubinsky
    The AAPS Journal, 20
  • [40] Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology Perspective
    Yanli Zhuang
    Di Chen
    Amarnath Sharma
    Zhenhua Xu
    The AAPS Journal, 20
12345